Analytical Data
-
Gene name
HLA-A*11:01&B2M&MAGE-A1(SLFRAVITK) Monomer
- Application
-
Alternative Names
HLA-A*1101 & B2M & MAGE-A1 (SLFRAVITK)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAV53343.1 (G25-T305)&P61769
-
Expression Region
AAV53343.1 (G25-T305)&P61769 (I21-M119)&SLFRAVITK
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*11:01-B2M-MAGE-A1(SLFRAVITK) monomeric recombinant protein is rooted in the fields of immunology and cancer research. HLA-A*11:01 is a significant human histocompatibility complex (HLA) class I molecule that plays a pivotal role in the presentation of antigens to CD8+ T cells, making it crucial for immune responses against tumors and viral infections. MAGE-A1 is a cancer/testis (CT) antigen that is typically expressed in various tumors but not in normal tissues, rendering it a promising target for immunotherapeutic interventions. The unique peptide SLFRAVITK, derived from MAGE-A1, is recognized by the HLA-A*11:01 molecule, facilitating the generation of an immune response. Understanding the structural and functional aspects of this protein complex is vital for developing novel cancer vaccines and T cell therapies. By exploring the interactions within this recombinant protein, researchers aim to enhance T cell recognition and activation, thus paving the way for targeted cancer therapies that can potentially improve patient outcomes in HLA-A*11:01 positive individuals. Furthermore, such studies contribute to the broader understanding of HLA-peptide interactions, shedding light on the intricate mechanisms of immune recognition and paving the way for more effective personalized medicine strategies.
